Final answer:
The label incorrectly indicates that AeroBid should be inhaled through the nostrils; it should be administered via oral inhalation for treating asthma.
Step-by-step explanation:
The error on the label is the route of administration for AeroBid. AeroBid is typically administered via oral inhalation rather than through the nostrils. The instructions on the label stating 'Inhale 2 puffs in nostrils twice daily' are incorrect as they suggest a nasal route instead of inhalation through the mouth.
AeroBid, which contains the active ingredient flunisolide, is a corticosteroid used for the maintenance treatment of asthma. The correct administration should involve inhaling the medication through the mouth into the lungs, where it can exert its anti-inflammatory effects. It is crucial for the effectiveness of the medication and to prevent any potential adverse effects that could result from improper delivery.
Pharmacists must ensure that the label on the medication reflects the correct usage instructions as provided in the prescription. In this case, revising the label to state 'Inhale 2 puffs orally twice daily' would rectify the error and ensure patient safety.